TOKYO, Jun 23 (Pulse News Wire) – Adr120s,inc. (3750.T) announced today that its subsidiary, ADR Therapeutics Co., Ltd., will begin launching a reproductive program for mares using NeoCella based on safety evaluations and joint research findings with Northern Farm.
The company decided to proceed with the commercialization of NeoCella following positive results from non-clinical trials and collaborative studies with Northern Farm. These studies included cases involving long-term barren mares and repeat breeders, which showed successful pregnancies. Based on these outcomes, ADR120S plans to gradually introduce NeoCella as a product managed by veterinarians within breeding programs. Scheduled milestones include internal approval, with the launch of the reproductive program beginning in July 2026.
Looking ahead, ADR120S intends to continue its collaboration with Northern Farm to further validate NeoCella's efficacy and safety through additional case studies. Additionally, the company is conducting joint research with Tokyo Medical University on the application of NeoCella for human endometritis and with Medical Arc Corporation for companion animals such as dogs. Any significant results from these ongoing projects will be disclosed appropriately. Regarding future impact on performance, ADR120S stated that the initial effects on the fiscal year ending March 2027 are expected to be minor.
The company will promptly disclose any material developments related to this initiative.
🟢 Confidence: High AI-translated content.